Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$5.59
-5.6%
$4.35
$3.51
$16.95
$48.47M0.28126,652 shs124,649 shs
Novogen Limited stock logo
KZIA
Novogen
$7.42
-7.6%
$8.43
$2.86
$39.05
$7.49M2.64589,235 shs31,930 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.55
+0.7%
$0.53
$0.39
$3.75
$39.80M-0.021.19 million shs698,631 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.80
-4.5%
$0.76
$0.66
$1.79
$33.65M1.64170,420 shs43,740 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
0.00%+50.25%+53.77%+15.40%-51.77%
Novogen Limited stock logo
KZIA
Novogen
0.00%-1.11%-20.89%+120.60%-59.85%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
0.00%+4.17%+32.34%-21.43%-80.29%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00%-2.90%+15.85%+0.95%-51.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3.8431 of 5 stars
3.40.00.04.62.32.50.6
Novogen Limited stock logo
KZIA
Novogen
3.9688 of 5 stars
3.85.00.00.03.00.00.0
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.179 of 5 stars
3.55.00.00.02.11.70.6
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
1.3854 of 5 stars
0.05.00.00.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.80
Moderate Buy$34.00508.23% Upside
Novogen Limited stock logo
KZIA
Novogen
3.50
Strong Buy$14.0088.68% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,224.18% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KZIA, SCYX, RANI, and KPTI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$42.00 ➝ $25.00
7/16/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/11/2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$27.00
7/10/2025
Novogen Limited stock logo
KZIA
Novogen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$13.00
6/11/2025
Novogen Limited stock logo
KZIA
Novogen
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
$145.24M0.33N/AN/A($22.10) per share-0.25
Novogen Limited stock logo
KZIA
Novogen
$1.51M4.96N/AN/A($9.87) per share-0.75
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M38.64N/AN/A$0.06 per share9.23
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.26M10.33N/AN/A$1.45 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)
Novogen Limited stock logo
KZIA
Novogen
-$17.56MN/A0.00N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.40N/A16.05N/A-599.05%-43.04%-28.21%11/5/2025 (Estimated)

Latest KZIA, SCYX, RANI, and KPTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 million
8/11/2025Q2 2025
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 million
8/7/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19-$0.18+$0.01-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/AN/AN/AN/AN/A
Novogen Limited stock logo
KZIA
Novogen
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
N/A
0.99
0.94
Novogen Limited stock logo
KZIA
Novogen
N/A
0.21
N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.54
0.54
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.20
5.20

Institutional Ownership

CompanyInstitutional Ownership
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
66.44%
Novogen Limited stock logo
KZIA
Novogen
30.89%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
2.75%
Novogen Limited stock logo
KZIA
Novogen
1.00%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
3808.67 million8.43 millionOptionable
Novogen Limited stock logo
KZIA
Novogen
121.01 million997,000Optionable
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11071.87 million39.47 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6041.93 million39.89 millionOptionable

Recent News About These Companies

SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday
SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Karyopharm Therapeutics stock logo

Karyopharm Therapeutics NASDAQ:KPTI

$5.59 -0.33 (-5.57%)
Closing price 04:00 PM Eastern
Extended Trading
$5.62 +0.03 (+0.45%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Novogen stock logo

Novogen NASDAQ:KZIA

$7.42 -0.61 (-7.60%)
Closing price 03:59 PM Eastern
Extended Trading
$7.61 +0.19 (+2.56%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.55 +0.00 (+0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.54 -0.02 (-3.21%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.80 -0.04 (-4.45%)
Closing price 04:00 PM Eastern
Extended Trading
$0.80 +0.00 (+0.31%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.